[CAS NO. 304896-28-4] AGK2
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:
PRODUCTS SPECIFICATIONS [304896-28-4]
Store
Catalog
SLK-S7577
Brand
Selleck
CAS
304896-28-4
DESCRIPTION [304896-28-4]
Overview
| MDL | MFCD01909444 |
|---|---|
| Molecular Weight | 434.27 |
| Molecular Formula | C23H13Cl2N3O2 |
| SMILES | O=C(NC1=C2C=CC=NC2=CC=C1)/C(C#N)=C/C3=CC=C(C4=CC(Cl)=CC=C4Cl)O3 |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3027 mL | 11.5136 mL | 23.0271 mL |
| 5 mM | 0.4605 mL | 2.3027 mL | 4.6054 mL |
| 10 mM | - | - | - |
| 50 mM | - | - | - |
Description
AGK2 is a potent, and selective inhibitor with of 3.5 μM that minimally affects either SIRT1 or SIRT3 at 10-fold higher levels.
Targets
| SIRT2 [1] (Cell-free assay) |
| 3.5 μM |
In vitro
In SIRT2-myc-expressing HeLa cells, AGK2 effectively inhibits the activity of SIRT2, and increases acetylated tubulin. AGK2 protects dopaminergic neurons from α-Syn–induced toxicity in primary midbrain cultures. AGK2 induces both necrosis and caspase-3-dependent apoptosis in C6 glioma cells. SIRT2 also decreases merlin-mutant viability of mouse schwann cells (MSCs) without substantially reducing wild-type MSC viability.
In vivo
In drosophila model of parkinson's disease, AGK2 rescues α-Syn–mediated toxicity and modify aggregation.
References
Powered by Arctom Copyright © 2026 Arctom. All rights
reserved.